News
A new study published in Mucosal Immunology shows that α-galactosylceramide (α-GalCer) serves as a potent adjuvant by activating natural killer T (NKT) cells, which promote effective cross ...
The patent claims include coverage of GRI-0803, the Company’s novel activator of human type 2 diverse NKT (dNKT) cells in development for the treatment of autoimmune disorders, with an initial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback